Aberdeen Group plc Buys 486,435 Shares of Caribou Biosciences, Inc. $CRBU

Key Points

• Aberdeen Group plc increased its stake in Caribou Biosciences, Inc. by 118.3%, owning approximately 0.97% of the company with a value of $1,131,000 after purchasing an additional 486,435 shares.
• In the second quarter, Caribou Biosciences reported a revenue of $2.67 million, exceeding expectations, and posted a loss of ($0.35) earnings per share, beating the consensus estimate by $0.05.
• The stock currently has an average rating of "Moderate Buy" from analysts and a consensus price target of $6.67.

Aberdeen Group plc increased its stake in Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) by 118.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 897,579 shares of the company's stock after purchasing an additional 486,435 shares during the quarter. Aberdeen Group plc owned approximately 0.97% of Caribou Biosciences worth $1,131,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Acadian Asset Management LLC bought a new stake in shares of Caribou Biosciences in the first quarter valued at $61,000. Jacobs Levy Equity Management Inc. increased its holdings in Caribou Biosciences by 19.4% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 1,442,121 shares of the company's stock worth $1,317,000 after acquiring an additional 234,052 shares during the last quarter. AQR Capital Management LLC raised its stake in Caribou Biosciences by 741.6% in the 1st quarter. AQR Capital Management LLC now owns 525,878 shares of the company's stock valued at $480,000 after acquiring an additional 463,391 shares during the period. Pale Fire Capital SE raised its stake in Caribou Biosciences by 7.2% in the 1st quarter. Pale Fire Capital SE now owns 786,722 shares of the company's stock valued at $718,000 after acquiring an additional 52,518 shares during the period. Finally, Nuveen LLC purchased a new stake in Caribou Biosciences during the first quarter valued at about $302,000. 77.51% of the stock is owned by institutional investors.

Caribou Biosciences Trading Down 1.5%

Shares of CRBU opened at $2.63 on Friday. Caribou Biosciences, Inc. has a 12-month low of $0.66 and a 12-month high of $3.00. The company has a market cap of $244.91 million, a PE ratio of -1.48 and a beta of 2.59. The stock has a 50-day moving average price of $2.05 and a 200-day moving average price of $1.53.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.35) earnings per share for the quarter, beating analysts' consensus estimates of ($0.40) by $0.05. Caribou Biosciences had a negative net margin of 1,800.93% and a negative return on equity of 62.35%. The business had revenue of $2.67 million for the quarter, compared to the consensus estimate of $1.64 million. As a group, analysts predict that Caribou Biosciences, Inc. will post -1.64 earnings per share for the current year.

Analyst Ratings Changes

CRBU has been the topic of several research reports. Wall Street Zen raised shares of Caribou Biosciences from a "sell" rating to a "hold" rating in a research report on Sunday, August 24th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Caribou Biosciences in a research note on Wednesday, October 8th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Caribou Biosciences presently has an average rating of "Moderate Buy" and a consensus price target of $6.67.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.